PURPOSE: We tested the hypothesis that the expression of cortactin and survivin in renal cell carcinomas (RCCs) correlates with more advanced stages of the disease. METHODS: Immunohistochemical analysis of cortactin and survivin expression (scored on a scale of 0-400) was performed in 124 renal cell carcinomas including clear cell renal cell carcinoma (CRCC), papillary RCC (PRCC), CRCC with sarcomatoid differentiation (SRCC), chromophobe RCC (ChRCC), and CRCC with granular cell differentiation (GRCC). RESULTS: Higher cortactin scores in CRCC were significantly correlated with higher T (p = 0.021) and N stages (p = 0.036), and nuclear grade (p = 0.012). Higher cortactin immunostaining scores were associated with higher mortality (p = 0.035). In addition, the survivin scores were significantly higher in the more aggressive GRCC and SRCC than in CRCC, suggesting a significant role of survivin expression in transformation of tumor cells to a more malignant phenotype. CONCLUSIONS: Higher expression of cortactin and survivin significantly correlated with advanced clinicopathological stage. Our findings support the potential targeting of survivin and cortactin for the development of novel therapeutic strategies for renal cell carcinoma.
PURPOSE: We tested the hypothesis that the expression of cortactin and survivin in renal cell carcinomas (RCCs) correlates with more advanced stages of the disease. METHODS: Immunohistochemical analysis of cortactin and survivin expression (scored on a scale of 0-400) was performed in 124 renal cell carcinomas including clear cell renal cell carcinoma (CRCC), papillary RCC (PRCC), CRCC with sarcomatoid differentiation (SRCC), chromophobe RCC (ChRCC), and CRCC with granular cell differentiation (GRCC). RESULTS: Higher cortactin scores in CRCC were significantly correlated with higher T (p = 0.021) and N stages (p = 0.036), and nuclear grade (p = 0.012). Higher cortactin immunostaining scores were associated with higher mortality (p = 0.035). In addition, the survivin scores were significantly higher in the more aggressive GRCC and SRCC than in CRCC, suggesting a significant role of survivin expression in transformation of tumor cells to a more malignant phenotype. CONCLUSIONS: Higher expression of cortactin and survivin significantly correlated with advanced clinicopathological stage. Our findings support the potential targeting of survivin and cortactin for the development of novel therapeutic strategies for renal cell carcinoma.
Authors: Paul Sweeney; Christopher G Wood; Louis L Pisters; Joel W Slaton; Ara Vaporciyan; Mark Munsell; Scott Carpenter; Joe Putnam; Stephen G Swisher; Garret Walsh; David Swanson; Colin P N Dinney Journal: Urol Oncol Date: 2003 Sep-Oct Impact factor: 3.498
Authors: Christopher J Ormandy; Elizabeth A Musgrove; Rina Hui; Roger J Daly; Robert L Sutherland Journal: Breast Cancer Res Treat Date: 2003-04 Impact factor: 4.872
Authors: Agnes G S H van Rossum; Ellen Schuuring-Scholtes; Vera van Buuren-van Seggelen; Philip M Kluin; Ed Schuuring Journal: BMC Genomics Date: 2005-02-14 Impact factor: 3.969
Authors: J H Gibcus; M F Mastik; L Menkema; G H de Bock; Ph M Kluin; Ed Schuuring; J E van der Wal Journal: Br J Cancer Date: 2008-02-12 Impact factor: 7.640
Authors: Claudia A Dumitru; Agnes Bankfalvi; Xiang Gu; Wilfried E Eberhardt; Reinhard Zeidler; Stephan Lang; Sven Brandau Journal: Front Immunol Date: 2013-02-18 Impact factor: 7.561